Singapore markets closed

Daiichi Sankyo Company, Limited (D4S.F)

Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
31.32-0.17 (-0.54%)
As of 08:25AM CEST. Market open.
Full screen
Previous close31.49
Open31.32
Bid31.18 x 50000
Ask32.12 x 50000
Day's range31.32 - 31.32
52-week range22.35 - 34.48
Volume191
Avg. volume116
Market cap61.007B
Beta (5Y monthly)0.26
PE ratio (TTM)50.52
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yield0.36 (1.15%)
Ex-dividend date27 Sept 2024
1y target estN/A
  • Zacks

    AstraZeneca (AZN) to Build $1.5B Cancer Drug Plant in Singapore

    This new plant will be AstraZeneca's (AZN) first manufacturing facility for producing novel antibody drug conjugates from start to finish. It is scheduled to open in 2029.

  • Reuters SG

    UPDATE 3-AstraZeneca to build $1.5-bln cancer drug plant in Singapore

    AstraZeneca plans to build a $1.5 billion manufacturing facility in Singapore to produce a promising category of cancer-killing drugs called antibody-drug conjugates (ADCs), the Anglo-Swedish drugmaker said on Monday. The facility, which will be the drugmaker's first end-to-end ADC production site, will be supported by the Singapore Economic Development Board. The company did not provide details on the possible financial incentives from the Singapore government.

  • Benzinga

    Heart Disease Drugmaker Esperion Therapeutics Reports Highest Revenue Yet, Stock Soars

    Tuesday, Esperion Therapeutics (NASDAQ:ESPR) reported first-quarter revenues of $137.74 million, up 467% Y/Y, surpassing the consensus of $84.51 million. The company reported an EPS of $0.34, a turnaround from an EPS loss of $(0.79) a year ago, beating the consensus of $0.05. U.S. net product revenue was $24.8 million, up approximately 46% Y/Y. Collaboration revenue was $113.0 million, compared to $7.3 million a year ago, driven by increased tablet sales to international partners and sales growt